S 3598119th CongressIn Committee

Better Care for PFAS Patients Act of 2026

Standard Summary
Balanced plain-English summary

This Senate bill requires the Director of the Agency for Toxic Substances and Disease Registry to contract with the National Academies of Sciences, Engineering, and Medicine (or another suitable entity) to assess the measurable human health effects of per- and polyfluoroalkyl substances (PFAS) and to develop clinical recommendations for addressing them. The agreement must be entered within 60 days of enactment, with an initial assessment and recommendations due within two years and updates at least every five years. The assessing entity must consult PFAS-exposed communities, and the Director must issue, post online, and distribute up-to-date clinical guidance to state and local public health authorities and health care professionals within five years, with periodic updates thereafter.

Key Points

  • 1Directs ATSDR to contract with the National Academies (or another entity) to assess PFAS health effects measurable in human tissue
  • 2Requires initial assessment and clinical recommendations within 2 years, updated at least every 5 years
  • 3Mandates engagement with PFAS-exposed communities to gather input on exposure, testing, and clinical follow-up
  • 4Requires ATSDR to issue, post publicly, and disseminate up-to-date clinical guidance to public health authorities and clinicians within 5 years

Impact Areas

Public health agenciesHealth care professionalsCommunities exposed to PFAS contaminationFederal research and scientific institutions
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026